AbbVie的新精神分裂药物在试验中失败,导致公司股票下降10%。 AbbVie's new schizophrenia drug fails in trials, causing a 10% drop in the company's stock.

AbbVie的实验性精神分裂药物Emraclidine在两个阶段的试验中都失败了,没有达到与安慰剂相比显著减少症状的目标。 AbbVie's experimental schizophrenia drug, emraclidine, failed in two Phase 2 trials, not meeting the goal of reducing symptoms significantly compared to a placebo. 尽管出现挫折, 导致阿伯维股价下跌超过10%, 公司报告称该药物被人很好地接受. Despite the setback, which caused AbbVie's stock to drop over 10%, the company reports that the drug was well-tolerated. 投资公司Cantor Fitzgerald仍对AbbVie的股票和输油管持乐观态度。 Investment firm Cantor Fitzgerald remains optimistic about AbbVie's stock and pipeline.